<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Immunopharmacology - Pharmacology and Pharmacotherapeutics</title>
    
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <link rel="stylesheet" href="../styles/main.css">
    
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams'
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <!-- Floating Table of Contents -->
    <div class="floating-toc" id="floating-toc">
        <div class="floating-toc-header">
            <span>üìë</span>
            <span>Contents</span>
        </div>
        <ul class="floating-toc-list">
            <!-- JS will populate this -->
        </ul>
    </div>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                <header class="document-header">
                    <div class="header-badge">
                        <span>üõ°Ô∏è</span>
                        <span>Section XV</span>
                    </div>
                    <h1 class="document-title">Immunopharmacology</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Vaccines, Sera, Immunosuppressants & Monoclonals</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>45 min read</span>
                        </div>
                    </div>
                </header>

                <main id="main-content" class="content-wrapper">
                    <!-- START: Chapter 73 -->
                    <section class="content-section" id="chapter-73">
                        <div class="section-header">
                            <div class="section-number">73</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíâ</span>
                                Vaccines and Antisera
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Immunity may be <strong>Active</strong> (production of antibodies by the individual) or <strong>Passive</strong> (transfer of antibodies from a donor).</p>

                            <h3>Active Immunisation (Vaccines)</h3>
                            <p>Vaccines are suspensions of dead or attenuated live microorganisms.</p>
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Type</th>
                                            <th>Examples</th>
                                            <th>Comments</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Live Attenuated</strong></td>
                                            <td>BCG, Oral Polio (Sabin), Measles, Mumps, Rubella (MMR), Varicella, Yellow Fever.</td>
                                            <td>Long lasting immunity (cellular + humoral). Avoid in pregnancy and immunocompromised.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Inactivated (Killed)</strong></td>
                                            <td>Pertussis (Whole cell), Injectable Polio (Salk), Rabies, Hepatitis A, Cholera, Plague.</td>
                                            <td>Humoral immunity mainly. Safe in immunocompromised.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Toxoids</strong></td>
                                            <td>Tetanus, Diphtheria.</td>
                                            <td>Modified toxins (non-toxic but immunogenic).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Subunit/Recombinant</strong></td>
                                            <td>Hepatitis B (HBsAg), HPV, Hib (Polysaccharide).</td>
                                            <td>Safe.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>

                            <h3>Passive Immunisation (Antisera/Immunoglobulins)</h3>
                            <p>Provides immediate but short-lived protection.
                            <br><strong>Human Ig:</strong> Tetanus Ig, Rabies Ig, Anti-D Ig (RhoGAM), Hepatitis B Ig.
                            <br><strong>Animal Sera (Equine):</strong> Tetanus Antitoxin (ATS), Diphtheria Antitoxin (ADS), Anti-Snake Venom (ASV), Anti-Rabies Serum (ARS). Risk of anaphylaxis and serum sickness (Sensitivity test mandatory).</p>

                            <h3>Management of Specific Bites/Stings</h3>
                            
                            <h4>1. Snake Bite</h4>
                            <p><strong>Polyvalent Anti-Snake Venom (ASV):</strong> Effective against Cobra, Krait, Russell's viper, and Saw-scaled viper.
                            <br><strong>Sensitivity Test:</strong> 0.1 ml diluted serum SC. If negative, give IV infusion.
                            <br><strong>Note:</strong> Neostigmine (+ Atropine) may be useful in cobra bite (neurotoxic) to reverse neuromuscular blockade.</p>

                            <h4>2. Scorpion Sting</h4>
                            <p>Venom causes massive release of catecholamines (Sympathetic storm) $\rightarrow$ Hypertension, pulmonary edema, arrhythmias.
                            <br><strong>Treatment:</strong>
                            <br>1. <strong>Prazosin:</strong> Alpha-blocker. Physiological antidote. 0.5 mg orally.
                            <br>2. <strong>Insulin-Glucose infusion:</strong> For metabolic support.
                            <br>3. <strong>Anti-Scorpion Venom:</strong> Specific antidote.
                            <br><em>Avoid:</em> Atropine, Morphine, Steroids (may worsen condition).</p>

                            <h4>3. Rabies</h4>
                            <p><strong>Post-exposure prophylaxis:</strong>
                            <br>1. <strong>Wound Care:</strong> Wash with soap/water immediately. Apply alcohol/iodine. Do not suture.
                            <br>2. <strong>Passive Immunisation:</strong> Rabies Immunoglobulin (RIG). Infiltrate around the wound.
                            <br>3. <strong>Active Immunisation:</strong> Anti-Rabies Vaccine (Cell culture vaccines) on days 0, 3, 7, 14, 28.</p>
                        </div>
                    </section>
                    <!-- END: Chapter 73 -->

                    <!-- START: Chapter 74 -->
                    <section class="content-section" id="chapter-74">
                        <div class="section-header">
                            <div class="section-number">74</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß¨</span>
                                Immunopharmacology
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Monoclonal Antibodies (mAbs)</h3>
                            <p>Antibodies produced by a single clone of B cells. Highly specific.
                            <br><strong>Nomenclature:</strong> -omab (mouse), -ximab (chimeric), -zumab (humanised), -umab (fully human).</p>

                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Drug</th>
                                            <th>Target</th>
                                            <th>Indication</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Infliximab / Adalimumab</strong></td>
                                            <td>TNF-$\alpha$</td>
                                            <td>Rheumatoid Arthritis, Crohn's, Psoriasis.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Rituximab</strong></td>
                                            <td>CD20 (B cells)</td>
                                            <td>Non-Hodgkin's Lymphoma, RA.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Trastuzumab</strong></td>
                                            <td>HER2/neu</td>
                                            <td>Breast Cancer.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Bevacizumab</strong></td>
                                            <td>VEGF</td>
                                            <td>Colorectal cancer, Macular degeneration (Intravitreal).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Abciximab</strong></td>
                                            <td>GpIIb/IIIa</td>
                                            <td>Antiplatelet (PCI).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Omalizumab</strong></td>
                                            <td>IgE</td>
                                            <td>Bronchial Asthma.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Basiliximab / Daclizumab</strong></td>
                                            <td>IL-2 Receptor (CD25)</td>
                                            <td>Renal transplant rejection prophylaxis.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>

                            <h3>Immunosuppressants</h3>
                            <p>Used to prevent organ transplant rejection and treat autoimmune diseases.</p>

                            <h4>1. Calcineurin Inhibitors</h4>
                            <p><strong>Cyclosporine:</strong> Inhibits calcineurin $\rightarrow$ blocks IL-2 production $\rightarrow$ inhibits T-cell activation.
                            <br><strong>Uses:</strong> Transplant rejection, Psoriasis, RA.
                            <br><strong>Toxicity:</strong> <strong>Nephrotoxicity</strong>, Hypertension, Hyperkalemia, Gum hypertrophy, Hirsutism.</p>
                            <p><strong>Tacrolimus:</strong> Macrolide antibiotic. Similar mechanism (binds FKBP). More potent. Toxicity: Nephrotoxicity, Neurotoxicity, Hyperglycemia.</p>

                            <h4>2. Antiproliferative Agents</h4>
                            <p><strong>Azathioprine:</strong> Converted to 6-mercaptopurine. Inhibits DNA synthesis.
                            <br><strong>Mycophenolate Mofetil:</strong> Inhibits IMP dehydrogenase (purine synthesis). Selective for lymphocytes.</p>

                            <h4>3. mTOR Inhibitors</h4>
                            <p><strong>Sirolimus (Rapamycin):</strong> Inhibits mTOR (mammalian Target of Rapamycin). Blocks T-cell proliferation. Side effects: Hyperlipidemia, Thrombocytopenia. Used in drug-eluting stents.</p>

                            <h3>Immunomodulators (Immunostimulants)</h3>
                            <ul>
                                <li><strong>Thalidomide:</strong> Inhibits TNF-$\alpha$ and angiogenesis.
                                    <br><strong>Uses:</strong> Erythema Nodosum Leprosum (Type 2 Lepra reaction), Multiple Myeloma.
                                    <br><strong>Adverse Effects:</strong> <strong>Teratogenicity (Phocomelia)</strong>, Peripheral neuropathy.</li>
                                <li><strong>Levamisole:</strong> Anthelmintic with immunostimulant property. Used in colon cancer (historical) and frequent viral infections.</li>
                                <li><strong>Interferons:</strong>
                                    <br><strong>IFN-$\alpha$:</strong> Hepatitis B/C, CML, Kaposi sarcoma.
                                    <br><strong>IFN-$\beta$:</strong> Multiple Sclerosis.
                                    <br><strong>IFN-$\gamma$:</strong> Chronic Granulomatous Disease.</li>
                                <li><strong>BCG:</strong> Intravesical instillation for bladder cancer.</li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Chapter 74 -->
                </main>

                <nav class="document-nav">
                    <div class="nav-container">
                        <a href="section-14.html" class="nav-button nav-button--large nav-button--previous">
                            <div class="nav-label">Previous</div>
                            <div class="nav-title">Section XIV: Skin & Eye</div>
                        </a>
                        
                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span>15</span>
                                <span class="progress-separator">/</span>
                                <span>16</span>
                            </div>
                        <a href="../index.html" class="nav-button nav-button--large">
                            <div class="nav-label">Go to</div>
                            <div class="nav-title">Index</div>
                        </a>
                            <div class="progress-bar-container">
                                <div class="progress-bar-fill" style="width: 93.75%;"></div>
                            </div>
                            <div class="progress-label">Section 15 of 16</div>
                        </div>
                        
                        <a href="section-16.html" class="nav-button nav-button--large nav-button--next">
                            <div class="nav-label">Next</div>
                            <div class="nav-title">Section XVI: Miscellaneous</div>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
        <div class="lightbox-backdrop"></div>
        <div class="lightbox-content">
            <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
            <img class="lightbox-image" src="" alt="">
            <p class="lightbox-caption"></p>
        </div>
    </div>

    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>